(C) Reuters. Marriott vs. InterContinental: Which Hotel Stock is a Better Buy?
Even though the spread of the COVID-19 Delta variant has presented a profound challenge to the hotel industry, the rapid vaccination drive and gradual easing of restrictions should help the industry endure. As people resume leisure travel, leading hotel operators Marriott (MAR) and InterContinental Hotels (IHG) should recover. But which of these stocks is a better buy now? Read more to find out.Bethesda, Md.-based Marriott International, Inc. (NASDAQ:MAR) operates, franchises, and licenses hotel, residential, and timeshare properties worldwide. The company operates through North American Full-Service; North American Limited-Service; and the Asia Pacific segments. In comparison, Denham, U.K.-based InterContinental Hotels Group PLC (IHG) owns, manages, franchises, and leases hotels in the Americas, Europe, Asia, the Middle East, Africa, and Greater China. The company also operates resorts, restaurants, and spas.
Tourism was one of the hardest-hit sectors last year due to the travel restrictions and social distancing mandates. However, thanks to the rapid rollout of the vaccines worldwide, people are regaining confidence and again engaging in leisure travel.
A stronger than expected summer leisure season this year is a clear indication of the rebounding hospitality industry. Lodging Analytics Research & Consulting (LARC) expects U.S. RevPAR to increase 49.9% in 2021 and at a 16.8% CAGR from 2020 – 2025. MAR and IHG are well-positioned to capitalize on rebounding demand.
Marriott vs. InterContinental: Which Hotel Stock is a Better Buy?
By Reuters – Oct 11, 2021
(Reuters) – Facebook Inc (NASDAQ:FB)’s oversight board, a body set up by the social network to give independent verdicts on a small number of thorny content decisions, said on…
By Investing.com – Oct 11, 2021
By Dhirendra Tripathi
Investing.com –Stocks gave back their gains on Monday as investors awaited third quarter earnings reports, which are bound to include plenty of talk about…
By Reuters – Oct 11, 2021
STOCKHOLM (Reuters) – Swedish drugmaker Orphan Biovitrum (SOBI) narrowed on Monday its full-year outlook to the upper end of the range, as it announced preliminary third-quarter…
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.